THURSDAY, Nov. 9, 2017 (HealthDay News) — Concentrations of cerebrospinal fluid (CSF) β42-amyloid 42 (Aβ42) derived from new immunoassays may show improved agreement with visual flutemetamol F18 ([18F]flutemetamol)-labeled positron emission tomography (PET) assessment, according to a study published online Nov. 6 in JAMA Neurology.
Shorena Janelidze, Ph.D., from Lund University in Sweden, and colleagues examined the concordance between CSF Aβ42 levels measured using five different immunoassays and visual amyloid PET analysis in a study involving 262 patients with mild cognitive impairment or subjective cognitive decline who had undergone [18F]flutemetamol-labeled PET. Levels of CSF Aβ42 were analyzed using the classic INNOTEST, modified INNOTEST, full automated Lumipulse (FL), EUROIMMUN (EI), and Meso Scale Discovery (MSD) assays.
The researchers found that the mass spectrometry-derived Aβ42 values showed higher correlations with the modified Aβ42-INNOTEST, Aβ42-FL, Aβ42-EI, and Aβ42-MSD assays versus the classic Aβ42-INNOTEST assay. Recombinant Aβ1-40 peptide partially quenched the signal in the classic Aβ42-INNOTEST assay. Better concordance with visual [18F]flutemetamol PET status was seen for the classic Aβ42-INNOTEST assay versus the newer assays (area under the receiver operating characteristic curve, 0.92 versus 0.87 to 0.89; P ≥ 0.01). When Aβ42-to-Aβ40, Aβ42-to-total tau, or Aβ42-to-phosphorylated tau ratios were used, the accuracies of the newer assays improved significantly.
“These findings suggest the benefit of implementing the CSF Aβ42-to-Aβ40 or Aβ42-to-tau ratios as a biomarker of amyloid deposition in clinical practice and trials,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry. GE Healthcare sponsored doses of [18F]flutemetamol injection, and EUROIMMUN provided test kits.
Copyright © 2017 HealthDay. All rights reserved.